Universal Biotech Completes Hundreds of Millions RMB Pre-IPO Financing Round with HAOYUE CAPITAL as Exclusive Financial Advisor

VCBeat (WeChat: vcbeat) has learned that Genesystem (Anhui) Co., Ltd. (“Genesystem”), a one-stop provider of biomedical services (scientific research, diagnostics, and new drug R&D) and raw materials based in Chuzhou, Anhui Province, recently announced the completion of its Pre-IPO financing round, amounting to hundreds of millions of RMB. The round was led by LYFE Capital, with participation from Kinghall Ventures, ADDOR, Huayi Venture Capital, and Ancheng Capital. Hapital served as the exclusive financial advisor for this financing round. The funds will be used to further expand Genesystem’s R&D infrastructure and enhance its business layout and market expansion in the life sciences sector, covering both services and raw materials, as well as CRO/CDMO offerings.

General Biotech was established in 2014, focusing on the development and translational application of products and technologies in the life sciences sector. The company is dedicated to building a comprehensive R&D and application platform for synthetic biology, leveraging its proprietary technologies across diverse fields ranging from basic life science research and biopharmaceutical development to the development of core raw materials for in vitro diagnostic products. It has emerged as an integrated provider of products and services for life science research and applications.

Panoramic View of General Biologics' Manufacturing Site

Leveraging its extensive experience in manufacturing operations and management accumulated over many years, the company has introduced advanced industrial management concepts across market intelligence, customer engagement, production process planning, and quality and cost control. This has enabled it to achieve industry-leading capabilities in cost and quality control, as well as rapid response times. Adhering to a market-driven approach that balances internal R&D iteration with external service excellence, the company deeply focuses on customers’ personalized needs, sustaining rapid business growth and continuously increasing its market share.

Advanced Industrialized Process Management

The Company currently operates five major business platforms: gene synthesis, industrial primers, analytical testing, protein expression, and antibody preparation, achieving “one-stop” service integration spanning genes, proteins, and antibodies. Among these, its gene synthesis and industrial primer platforms are industry leaders in both technology and scale. The Company is strategically focusing on three core business lines: life science research services/products, core raw materials and services for diagnostic reagents, and early-stage drug discovery services.

• Life Science Research offers a comprehensive suite of solutions, including DNA/RNA synthesis, genetic engineering (gene synthesis, vector construction), sequencing services, recombinant protein (antibody) expression, antibody preparation, and research reagents.

• Core raw materials for IVD diagnostic reagents cover three major fields: molecular diagnostics, immunodiagnostics, and clinical chemistry. In the field of molecular diagnostics, we provide probes and primers, PCR enzyme systems, molecular diagnostic enzymes, and positive quality control materials covering PCR platforms, NGS platforms, and CRISPR platforms. In the field of immunodiagnostics, we offer diagnostic antigens, antibodies, and blockers covering lateral flow immunoassay platforms, chemiluminescence immunoassay platforms, and colloidal gold platforms. Additionally, in the field of clinical chemistry diagnostics, we supply biochemicals, diagnostic enzymes, calibrators, and quality control materials.

• Early-stage new drug R&D services provide DEL small-molecule lead compound library primers, pharmaceutical nucleic acid CMC/CDMO services, plasmid CRO/CDMO services, Trimer libraries, recombinant antibodies, CRO/CDMO services for biologic macromolecular protein antibody drugs, and stable cell line construction services.

Yong Jingui, Chairman and General Manager of Universal BioIt stated that, against the backdrop of centralized drug procurement in China, the domestic substitution of biopharmaceutical reagents and raw materials has become a major industry trend. Born from cross-industry integration, General Biology adheres to an industrial mindset in the research, development, and production of biopharmaceutical raw materials. Leveraging advanced equipment and concepts, the company is committed to reducing industry costs, strengthening China’s raw material market, and continuously establishing and innovating national industry standards. The company prioritizes R&D investment, holding 10 invention patents, having submitted six national standards for approval, with two already approved. Since its establishment, relying on leading industrial concepts, comprehensive one-stop services, and top-tier market response speed, the company has expanded its business to over 5,000 institutions, achieving a compound annual growth rate (CAGR) of more than 50%.

Genesand will continue to deepen its roots in the life sciences, pharmaceuticals, and diagnostic raw materials industries, providing one-stop CRO/CDMO solutions to global life science research institutions, pharmaceutical companies, and IVD manufacturers, with the aim of becoming a global one-stop supplier of biopharmaceutical raw materials and services. We are honored to welcome new institutional shareholders, including Jifeng Capital, Kinghall Ventures, ADDOR, Huayi Venture Capital, and Ancheng Capital. I believe that with the support of all shareholders, Genesand is poised to set sail on a new journey of growth. We also extend our gratitude to the Hapital Capital team, the exclusive financial advisor for this round of financing, whose professionalism and dedication have been widely recognized.

Hu Xuyu, Partner at Jifeng CapitalIt stated that in recent years, the diagnostics and biopharmaceutical R&D markets have flourished, with substantial market space and clear growth trends for core raw materials and services. General Biosystems is an industry-leading one-stop integrated platform for research/IVD/new drug R&D raw materials and services. It has introduced advanced industrial thinking into the biotechnology sector, featuring highly automated production processes and high-quality, stable products. Leveraging powerful synthetic biology technologies, its business spans multiple fields, from basic life sciences research to preclinical biologics discovery, genetic engineering vaccine development, nucleic acid drug and gene therapy R&D, and the development of core raw materials for in vitro diagnostic products. The founding team possesses strategic vision, strong management capabilities, and exceptional execution. We remain bullish on the company’s long-term development and look forward to its continued efforts in active international expansion, providing high-quality, comprehensive products and services to global biopharmaceutical R&D and diagnostics customers, thereby fostering innovation in R&D.

KinghallWang Zhifei, Managing Director of Kinghall VenturesHe stated that with the rapid development of life sciences in China and the overall rise of the industrial chain, the upstream sector has gained significant room for growth. Since its establishment, General Biosystems has pursued a high-starting-point and high-standard strategy, rapidly expanding into the markets for scientific research, diagnostics, and new drug R&D. The company’s founding team boasts extensive management experience and strong entrepreneurial drive. We are honored to participate in this financing round and believe that the company will deliver higher-quality products and services to diverse customers, thereby making its own contribution to the development of the industry.

Xue Yi, Senior Partner at ADDORIt was stated that China’s life sciences and biopharmaceutical industries have developed rapidly in recent years, driving sustained demand for upstream services and raw materials. Starting with gene synthesis services, General Biosystems has established an integrated service chain covering genes, proteins, and antibodies within just a few years. The company has experienced rapid business growth and a continuous increase in its customer base. ADDOR has long been acquainted with the management team of General Biosystems and has witnessed the company’s rapid growth. We highly recognize the team’s entrepreneurial spirit, management capabilities, and service efficiency, and are optimistic about the company’s future development prospects.

Hu Qisheng, General Manager of Ancheng CapitalIt was stated that in recent years, the surge in domestic pharmaceutical innovation, supportive policies, and the influx of overseas orders have driven rapid development in the market for core raw materials and services in diagnostics and biopharmaceuticals. As a standout company in the industry, GenScript’s management team boasts many years of industry experience, a deep understanding of industrialization mindset, unique strategic vision, excellent overall execution capabilities, and strong motivation. It is precisely this team that has enabled the company to achieve the leap from 0 to 1 in a short period, quickly emerging as a prominent player in the industry and building a one-stop, full-product-line platform spanning three major business pipelines: core raw material services for diagnostic reagents, raw materials and services for new drug R&D, and products and services for life sciences research. We believe the company will continue to maintain strong momentum, consistently providing high-quality and comprehensive products and services to global customers.

Li Yishi, Partner at Haoyue Capitalstated that it was pleased to have successfully completed the Pre-IPO financing round in partnership with General Biosystems, a one-stop supplier of biopharmaceutical raw materials and services. The domestic market for biopharmaceutical raw materials and services is highly fragmented and remains in the early stages of competition. Against this backdrop, the management team of General Biosystems has distinguished itself in the industry by rapidly achieving comprehensive product portfolio coverage and global business expansion, leveraging advanced manufacturing concepts and strong execution capabilities. The injection of capital from this financing round will further accelerate the company’s global expansion. We look forward to General Biosystems continuing to innovate, establishing more Chinese standards, and making greater contributions to the raw materials and services sector for China’s biopharmaceutical and diagnostic industries.

JF Capital is a healthcare-focused investment fund established in 2015, currently managing approximately $1.4 billion in assets. We are dedicated to investing in healthcare companies with exceptional management teams and compelling visions, focusing on sectors such as biopharmaceuticals, medical devices, and medical diagnostics. We work closely with our portfolio companies, providing not only financial support but also assistance in business development, identifying overseas partners, and actively supporting strategic and team enhancements to facilitate product approvals and market access. For JF Capital, portfolio companies are not merely investment projects, but long-term partners.

Kinghall Ventures is an investment institution focused on the healthcare sector, headquartered in Guangzhou. The core team of its fund manager possesses over 25 years of experience in the medical industry and successfully built KingMed Diagnostics, China’s largest third-party medical testing laboratory. Currently, Kinghall Ventures manages two healthcare industry funds with a total scale of nearly RMB 2 billion. The firm continues to make strategic investments in areas such as in vitro diagnostics (IVD) to build an industrial ecosystem, committed to leveraging the synergy between industry and capital to cultivate healthcare enterprises with international competitiveness.

ADDOR was established through the mixed-ownership reform within Jiangsu High-Tech Investment Group, a well-established and renowned venture capital firm. It ranks among the industry leaders in terms of industry research capabilities, assets under management (AUM), and investment specialization, standing as one of the most influential venture capital institutions in China. As of March 2021, ADDOR’s management team had cumulatively managed RMB 113.7 billion in capital, invested in and supported 987 startups, and helped 207 of these companies list on domestic and international capital markets. ADDOR pursues long-term value, invests in cutting-edge technologies, fosters a leading corporate culture, and continuously builds superior capabilities. Over the years, with VC/PE business at its core and guided by client needs, ADDOR has strategically expanded into real estate funds, M&A funds, and funds of funds (FOFs), progressively perfecting its comprehensive asset management platform.

Huayi Venture Capital is a professional platform-based venture capital investment management firm, with its core business focused on the investment, management, and operation of venture capital funds in the technology and manufacturing sectors. Its limited partners include top-tier domestic strategic and industrial institutional investors such as Tsinghua Holdings, Zhejiang Financial Holdings, Yiwu Financial Holdings, China Commodities City Group, Century Golden Resources, Zhuzhou State-owned Investment Holding, and JMC Motors. Representative portfolio companies include Chian Technology (300523), Daily Interactive (300766), Jianlong Micro-Nano (688357), Daxin Semiconductor, and OnMicro. Currently, the independently managed assets under management amount to RMB 7.8 billion, while the cumulative co-managed assets reach RMB 20 billion. Originating from the former Investment Department of Tsinghua Holdings, Huayi Venture Capital’s core team has long been deeply engaged in the Tsinghua industrial investment system. The team has successively established and managed industry-leading brands such as Tsinghua Holdings Venture Capital and Tsinghua Holdings Fund of Funds, possessing extensive resources in the venture capital industry and rich fund management experience.

Ancheng Capital, established in 2016, serves as the equity investment platform under Jian’an Investment Holding Group. The company focuses its investments primarily on healthcare, high-end manufacturing, and TMT sectors. By leveraging fund-of-funds, direct equity investments, and market-oriented co-investments, it has built a diversified equity investment system covering the entire corporate lifecycle. Currently, the company manages approximately RMB 12 billion in funds and has established long-term partnerships with over 30 outstanding private equity fund managers. In recent years, the company has consecutively received numerous accolades, including recognition in the “China Investment Institution LP Activity Ranking” and being named among the “Top 10 Market-Oriented Fund-of-Funds.”

HaoYue Capital, founded in January 2014, is dedicated to serving as a bridge connecting China’s healthcare sector with capital. Its research and transaction coverage spans multiple sub-sectors, including biopharmaceuticals, innovative medical devices, in vitro diagnostics (IVD) and precision medicine, healthcare services, and smart healthcare. The HaoYue Capital team comprises senior investment bankers with extensive experience in China’s healthcare industry. By closely monitoring market dynamics and investment trends in the healthcare sector over the long term, the firm publishes weekly healthcare investment reports and thematic research studies, offering HaoYue’s perspectives on new policies and emerging frontiers.